D. Rischin, M. R. Migden, A. L. S. Chang, and E. al., “Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma”, J of Skin, vol. 2, p. S79, Dec. 2018.